Mechanisms and consequences of inflammatory signaling in the myocardium

Current Hypertension Reports

Volumn 14, Issue 6, 2012, Pages 510-516

  Ahn, Jihyun ^a   Kim, Jaetaek ^a  

^a Chung Ang University   (South Korea)

Author keywords

Chemokine; Cytokine; Heart failure; Inflammasome; Interleukin; Ischemia reperfusion; Myocardial inflammation; Nuclear factor kappaB; Protease; Protease activated receptors; Reactive oxygen species; Receptor activator of nuclear factor kappaB ligand; Tumor necrosis factor; Ventricular remodeling

Indexed keywords

ANTIINFLAMMATORY AGENT; CHEMOKINE RECEPTOR CX3CR1; ETANERCEPT; FLUINDOSTATIN; GLUCOCORTICOID; I KAPPA B KINASE ALPHA; I KAPPA B KINASE BETA; I KAPPA B KINASE GAMMA; IMMUNOGLOBULIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; METHYLPREDNISOLONE; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; PENTOXIFYLLINE; PHOSPHOLIPASE A2; PLACEBO; PROTEINASE ACTIVATED RECEPTOR; TOLL LIKE RECEPTOR 4;

ARTICLE; CARDITIS; CELL PROTECTION; CHEMOTAXIS; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE SEVERITY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME METABOLISM; EXTRACELLULAR MATRIX; GENE TRANSLOCATION; HEART DILATATION; HEART FAILURE; HEART INFARCTION; HEART MUSCLE; HEART VENTRICLE REMODELING; HUMAN; IMMUNOREACTIVITY; LEUKOCYTE; OSTEOCLAST; OSTEOLYSIS; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN MOTIF; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; UPREGULATION;

CARDIOMYOPATHIES; HEART FAILURE; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; SIGNAL TRANSDUCTION; VENTRICULAR REMODELING;

EID: 84870545235     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-012-0309-0     Document Type: Article

References (89)

1. Fang J, Mensah GA, Croft JB, et al. Heart failure-related hospitalization in theU.S., 1979 to 2004. JAmColl Cardiol. 2008;52:428-34.
2. Schocken DD, Benjamin EJ, Fonarow GC, et al. Prevention of heart failure: a scientific statement from the American Heart Association Councils on Epidemiology and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group. Circulation. 2008;117:2544-65.
3. Velagaleti RS, Pencina MJ, Murabito JM, et al. Long-term trends in the incidence of heart failure after myocardial infarction. Circulation. 2008;118:2057-62.
4. Kalogeropoulos AP, Georgiopoulou VV, Butler J. From risk factors to structural heart disease: the role of inflammation. Heart Fail Clin. 2012;8:113-23.
5. Marchant D, Boyd J, Lin D, et al. Inflammation in myocardial diseases. Circ Res. 2012;110:126-44. This article addresses the specific pathways and mechanisms contributing to cardiac dysfunction in four classic settings marked by inflammation: ischemiareperfusion injury, sepsis, myocarditis, and transplant rejection.
6. Hohensinner PJ, Niessner A, Huber K, et al. Inflammation and cardiac outcome. Curr Opin Infect Dis. 2011;24:259-64.
7. Mann DL. The emerging role of innate immunity in the heart and vascular system: for whom the cell tolls. Circ Res. 2011;108:1133-45. This article reviews the biology of innate immune signaling in the heart, suggesting that the innate immune system is involved in the pathogenesis of atherosclerosis, acute coronary syndromes, stroke, viral myocarditis, sepsis, ischemia/reperfusion injury, and heart failure.
8. Heymans S, Hirsch E, Anker SD, et al. Inflammation as a therapeutic target in heart failure? A scientific statement from the translational research committee of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2009;11:119-29.
9. Mohammed SF, Storlie JR, Oehler EA, et al. Variable phenotype in murine transverse aortic constriction. Cardiovasc Pathol. 2012;21:188-98.
10. Kolattukudy PE, Niu J. Inflammation, endoplasmic reticulum stress, autophagy, and the monocyte chemoattractant protein-1/CCR2 pathway. Circ Res. 2012;110:174-89. This article reviews the role of ER stress and inflammation, with an emphasis on newly discovered roles for the chemokine monocyte chemoattractant protein-1 (MCP-1) and its downstream effector and novel zinc finger protein, MCP-1-induced protein.
11. Mitchell JA, Ryffel B, Quesniaux VF, et al. Role of patternrecognition receptors in cardiovascular health and disease. Biochem Soc Trans. 2007;35:1449-52.
12. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell. 2010;140:805-20.
13. Schroder K, Tschopp J. The inflammasomes. Cell. 2010;140:821-32.
14. Feng Y, Chao W. Toll-like receptors and myocardial inflammation. Int J Inflam. 2011;2011:170352.
15. Chao W. Toll-like receptor signaling: a critical modulator of cell survival and ischemic injury in the heart. Am J Physiol Heart Circ Physiol. 2009;296:H1-12.
16. Antoniak S, Pawlinski R, Mackman N. Protease-activated receptors and myocardial infarction. IUBMB Life. 2011;63:383-9.
17. Sabri A, Muske G, Zhang H, et al. Signaling properties and functions of two distinct cardiomyocyte protease-activated receptors. Circ Res. 2000;86:1054-61.
18. Glembotski CC, Irons CE, Krown KA, et al. Myocardial a-thrombin receptor activation induces hypertrophy and increases atrial natriuretic factor gene expression. J Biol Chem. 1993;268:20646-52.
19. Strande JL, Hsu A, Su J, et al. SCH 79797, a selective PAR1 antagonist, limits myocardial ischemia/reperfusion injury in rat hearts. Basic Res Cardiol. 2007;4:350-8.
20. Antoniak S, Rojas M, Spring D, et al. Protease-activated receptor 2 deficiency reduces cardiac ischemia/reperfusion injury. Arterioscler Thromb Vasc Biol. 2010;30:2136-42.
21. Napoli C, De Nigris F, Cicala C, et al. Protease-activated receptor-2 activation improves efficiency of experimental ischemic preconditioning. Am J Physiol Heart Circ Physiol. 2002;282:H2004-10.
22. Barnes PJ, Karin M. Nuclear factor-?B: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med. 1997;336:1066-71.
23. Chen LW, Egan L, Li ZW, et al. The two faces of IKK and NF-?B inhibition: prevention of systemic inflammation but increased local injury following intestinal ischemia-reperfusion. Nat Med. 2003;9:575-81.
24. Mustapha S, Kirshner A, De Moissac D, et al. A direct requirement of nuclear factor-?B for suppression of apoptosis in ventricular myocytes. Am J Physiol Heart Circ Physiol. 2000;279:H939-45.
25. Baetz D, Regula KM, Ens K, et al. Nuclear factor-?B-mediated cell survival involves transcriptional silencing of the mitochondrial death gene BNIP3 in ventricular myocytes. Circulation. 2005;112:3777-85.
26. Werner SL, Barken D, Hoffmann A. Stimulus specificity of gene expression programs determined by temporal control of IKK activity. Science. 2005;309:1857-61.
27. Gordon JW, Shaw JA, Kirshenbaum LA. Multiple facets of NF-?B in the heart: to be or not to NF-?B. Circ Res. 2011;108:1122-32. This study provides evidence of the duality of beneficial and deleterious effects of NF-?B in the heart such as potentially harmful inflammation as well as promoting cardiomyocyte survival.
28. Coggins M, Rosenzweig A. The fire within: cardiac inflammatory signaling in health and disease. Circ Res. 2012;110:116-25. This article introduces inflammatory pathways in the heart, as well as their interactions with signaling pathways regulating cell survival and metabolism.
29. This article introduces inflammatory pathways in the heart, as well as their interactions with signaling pathways regulating cell survival and metabolism. 29. Van der Heiden K, Cuhlmann S, le Luong A, et al. Role of nuclear factor ?B in cardiovascular health and disease. Clin Sci (Lond). 2010;118:593-605.
30. Michel MC, Li Y, Heusch G. Mitogen-activated protein kinases in the heart. Naunyn Schmiedebergs Arch Pharmacol. 2001;363:245-66.
31. Demyanets S, Kaun C, Rychli K, et al. The inflammatory cytokine oncostatin M induces PAI-1 in human vascular smooth muscle cells in vitro via PI 3-kinase and ERK1/2-dependent pathways. Am J Physiol Heart Circ Physiol. 2007;293:H1962-8.
32. Heidbreder M, Naumann A, Tempel K, et al. Remote vs. ischaemic preconditioning: the differential role of mitogen-activated protein kinase pathways. Circ Res. 2008;78:108-15.
33. Aoki H, Kang PM, Hampe J, et al. Direct activation of mitochondrial apoptosis machinery by c-Jun N-terminal kinase in adult cardiac myocytes. J Biol Chem. 2002;277:10244-50.
34. Remondino A, Kwon SH, Communal C, et al. ß-adrenergic receptor-stimulated apoptosis in cardiac myocytes is mediated by reactive oxygen species/c-Jun NH2-terminal kinase-dependent activation of the mitochondrial pathway. Circ Res. 2003;92:136-8.
35. Andreka P, Zang J, Dougherty C, et al. Cytoprotection by Jun kinase during nitric oxide-induced cardiac myocyte apoptosis. Circ Res. 2001;88:305-12.
36. Dougherty CJ, Kubasiak LA, Prentice H, et al. Activation of c-Jun N-terminal kinase promotes survival of cardiac myocytes after oxidative stress. Biochem J. 2002;362:561-71.
37. Communal C, Colucci WS, Singh K. p38 mitogen-activated protein kinase pathway protects adult rat ventricular myocytes against ß-adrenergic receptor-stimulated apoptosis. Evidence for Gidependent activation. J Biol Chem. 2000;275:19395-400.
38. Schneider S, Chen W, Hou J, et al. Inhibition of p38 MAPK a/ß reduces ischemic injury and does not block protective effects of preconditioning. Am J Physiol Heart Circ Physiol. 2001;280: H499-508.
39. Mascareno E, Dhar M, Siddiqui MA. Signal transduction and activator of transcription (STAT) protein-dependent activation of angiotensinogen promoter: a cellular signal for hypertrophy in cardiac muscle. Proc Natl Acad Sci U S A. 1998;95:5590-4.
40. Boengler K, Hilfiker-Kleiner D, Drexler H, et al. The myocardial JAK/STAT pathway: from protection to failure. Pharmacol Ther. 2008;120:172-85.
41. Fujio Y, Nguyen T, Wencker D, et al. Akt promotes survival of cardiomyocytes in vitro and protects against ischemia-reperfusion injury in mouse heart. Circulation. 2000;101:660-7.
42. Syed FM, Hahn HS, Odley A, et al. Proapoptotic effects of caspase-1/interleukin-converting enzyme dominate in myocardial ischemia. Circ Res. 2005;96:1103-9.
43. Tschopp J, Schroder K. NLRP3 inflammasome activation: The convergence of multiple signalling pathways on ROS production? Nat Rev Immunol. 2010;10:210-5.
44. Kawaguchi M, Takahashi M, Hata T, et al. Inflammasome activation of cardiac fibroblasts is essential for myocardial ischemia/reperfusion injury. Circulation. 2011;123:594-604.
45. Palmer JN, Hartogensis WE, Patten M, et al. Interleukin-1ß induces cardiac myocyte growth but inhibits cardiac fibroblast proliferation in culture. J Clin Invest. 1995;95:2555-64.
46. Van Tassell BW, Arena RA, Toldo S, et al. Enhanced interleukin-1 activity contributes to exercise intolerance in patients with systolic heart failure. PLoS One. 2012;7:e33438.
47. Kurdi M, Randon J, Cerutti C, et al. Increased expression of IL-6 and LIF in the hypertrophied left ventricle of TGR(mRen2)27 and SHR rats. Mol Cell Biochem. 2005;269:95-101.
48. Sano M, Fukuda K, Kodama H, et al. Interleukin-6 family of cytokines mediate angiotensin II-induced cardiac hypertrophy in rodent cardiomyocytes. J Biol Chem. 2000;275:29717-23.
49. Wang M, Markel TA, Meldrum DR. Interleukin 18 in the heart. Shock. 2008;30:3-10.
50. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998;93:165-76.
51. Kim YM, Kim YM, Lee YM, et al. TNF-related activation-induced cytokine (TRANCE) induces angiogenesis through the activation of Src and phospholipase C (PLC) in human endothelial cells. J Biol Chem. 2002;277:6799-805.
52. Min JK, Kim YM, Kim SW, et al. TNF-related activation-induced cytokine enhances leukocyte adhesiveness: induction of ICAM-1and VCAM-1 via TNF receptor-associated factor and protein kinase C-dependent NF-?B activation in endothelial cells. J Immunol. 2005;175:531-40.
53. Min JK, Cho YL, Choi JH, et al. Receptor activator of nuclear factor (NF)-?B ligand (RANKL) increases vascular permeability: impaired permeability and angiogenesis in eNOS-deficient mice. Blood. 2007;109:1495-502.
54. Ueland T, Yndestad A, Øie E, et al. Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure. Circulation. 2005;111:2461-8.
55. Ock S, Ahn J, Lee SH, et al. Receptor activator of nuclear factor-?B ligand is a novel inducer of myocardial inflammation. Cardiovasc Res. 2012;94:105-14.
56. Niu J, Kolattukudy PE. Role of MCP-1 in cardiovascular disease: molecular mechanisms and clinical implications. Clin Sci (Lond). 2009;117:95-109.
57. Hayashidani S, Tsutsui H, Shiomi T, et al. Anti-monocyte chemoattractant protein-1 gene therapy attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation. 2003;108:2134-40.
58. Frangogiannis NG. Regulation of the inflammatory response in cardiac repair. Circ Res. 2012;110:159-73. This review introduces recently identified endogenous inhibitors induced as part of the core inflammatory reaction that serve to reduce post-infarct inflammation.
59. Liehn EA, Postea O, Curaj A, et al. Repair after myocardial infarction, between fantasy and reality: the role of chemokines. J Am Coll Cardiol. 2011;58:2357-62.
60. Säemann MD, Haidinger M, Hecking M, et al. The multifunctional role of mTOR in innate immunity: implications for transplant immunity. Am J Transplant. 2009;9:2655-61.
61. Weichhart T, Costantino G, Poglitsch M, et al. The TSC-mTOR signaling pathway regulates the innate inflammatory response. Immunity. 2008;29:565-77.
62. Song X, Kusakari Y, Xiao CY, et al. mTOR attenuates the inflammatory response in cardiomyocytes and prevents cardiac dysfunction in pathological hypertrophy. Am J Physiol Cell Physiol. 2010;299:C1256-66.
63. Deten A, Hölzl A, Leicht M, et al. Changes in extracellular matrix and in transforming growth factor beta isoforms after coronary artery ligation in rats. J Mol Cell Cardiol. 2001;33:1191-207.
64. Kuwahara F, Kai H, Tokuda K, et al. Transforming growth factor-ß function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats. Circulation. 2002;106:130-5.
65. Sun Y. Myocardial repair/remodelling following infarction: roles of local factors. Cardiovasc Res. 2009;81:482-90.
66. Rosenkranz S. TGF-ß1 and angiotensin networking in cardiac remodeling. Cardiovasc Res. 2004;63:423-32.
67. Chapman RE, Spinale FG. Extracellular protease activation and unraveling of the myocardial interstitium: critical steps toward clinical applications. Am J Physiol Heart Circ Physiol. 2004;286:H1-10.
68. Flores-Arredondo JH, García-Rivas G, Torre-Amione G. Immune modulation in heart failure: past challenges and future hopes. Curr Heart Fail Rep. 2011;8:28-37.
69. Kempf T, Zarbock A, Vestweber D, et al. Anti-inflammatory mechanisms and therapeutic opportunities in myocardial infarct healing. J Mol Med (Berl). 2012;90:361-9. This article reviews anti-inflammatory and pro-inflammatory pathways during myocardial infarct healing.
70. Madias JE, Hood Jr. WB. Effects of methylprednisolone on the ischemic damage in patients with acute myocardial infarction. Circulation. 1982;65:1106-13.
71. Mann DL, McMurray JJ, Packer M, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation. 2004;109:1594-602.
72. Mann DL, Bozkurt B, Torreamione G, et al. Effect of the soluble TNF-antagonist etanercept on tumor necrosis factor bioactivity and stability. Clin Transl Sci. 2008;1:142-5.
73. Chung ES, Packer M, Lo KH, et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-a, in patients with moderate-tosevere heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation. 2003;107:3133-40.
74. Kotyla PJ, Owczarek A, Rakoczy J, et al. Infliximab treatment increases left ventricular ejection fraction in patients with rheumatoid arthritis: assessment of heart function by echocardiography, endothelin 1, interleukin 6, and NT-pro brain natriuretic peptide. J Rheumatol. 2012;39:701-6.
75. Shaw SM, Shah MK, Williams SG, et al. Immunological mechanisms of pentoxifylline in chronic heart failure. Eur J Heart Fail. 2009;11:113-8.
76. Bahrmann P, Hengst UM, Richartz BM, et al. Pentoxifylline in ischemic, hypertensive and idiopathic-dilated cardiomyopathy: effects on left-ventricular function, inflammatory cytokines and symptoms. Eur J Heart Fail. 2004;6:195-201.
77. Nussinovitch U, Shoenfeld Y. Intravenous immunoglobulin -indications and mechanisms in cardiovascular diseases. Autoimmun Rev. 2008;7:445-52.
78. Suri V, Varma S, Joshi K, et al. Lupus myocarditis: marked improvement in cardiac function after intravenous immunoglobulin therapy. Rheumatol Int. 2010;30:1503-5.
79. McNamara DM, Holubkov R, Starling RC, et al. Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy. Circulation. 2001;103:2254-9.
80. Földes G, von Haehling S, Okonko DO, et al. Fluvastatin reduces increased blood monocyte Toll-like receptor 4 expression in whole blood from patients with chronic heart failure. Int J Cardiol. 2008;124:80-5.
81. Yang J, Zhang XD, Yang J, et al. The cardioprotective effect of fluvastatin on ischemic injury via down-regulation of toll-like receptor 4. Mol Biol Rep. 2011;38:3037-44.
82. Okopien B, Kowalski J, Krysiak R, et al. Monocyte suppressing action of fenofibrate. Pharmacol Rep. 2005;57:367-72.
83. Huang WP, Yin WH, Chen JW, et al. Fenofibrate attenuates endothelial monocyte adhesion in chronic heart failure: an in vitro study. Eur J Clin Invest. 2009;39:775-83.
84. Liu H, Li W, Gu W, et al. Immunoregulatory effects of carvedilol on rat experimental autoimmune myocarditis. Scand J Immunol. 2010;71:38-44.
85. Satoh M, Ishikawa Y, Minami Y, et al. Eplerenone inhibits tumour necrosis factor a shedding process by tumour necrosis factor a converting enzyme in monocytes from patients with congestive heart failure. Heart. 2006;92:979-80.
86. Frangogiannis NG, Dewald O, Xia Y, et al. Critical role of monocyte chemoattractant protein-1/CC chemokine ligand 2 in the pathogenesis of ischemic cardiomyopathy. Circulation. 2007;115:584-92.
87. Gilbert J, Lekstrom-Himes J, Donaldson D, et al. Effect of CC chemokine receptor 2 CCR2 blockade on serum C-reactive protein in individuals at atherosclerotic risk and with a single nucleotide polymorphism of the monocyte chemoattractant protein-1 promoter region. Am J Cardiol. 2011;107:906-11.
88. Arefieva TI, Krasnikova TL, Potekhina AV, et al. Synthetic peptide fragment (65-76) of monocyte chemotactic protein-1 (MCP-1) inhibits MCP-1 binding to heparin and possesses antiinflammatory activity in stable angina patients after coronary stenting. Inflamm Res. 2011;60:955-64.
89. Aukrust P, Gullestad L, Ueland T, et al. Inflammatory and antiinflammatory cytokines in chronic heart failure: potential therapeutic implications. Ann Med. 2005;37:74-85.